| Acquired by | Shire |
| Price | $160M |
| Date | 3/13 |
| Terms | Cash |
| Website | sarcode.com |
| Category | BioTech |
| SARcode@sarcode.com | |
| Employees | |
| Founded | 2006 |
| TOTAL | $73M |
| FUNDING TOTAL | $73M |
| Venture Round, 12/06 Alta Partners Clarus Ventures | $29M |
| Series B, 7/11 Sofinnova Ventures Rho Capital Partners Alta Partners Clarus Ventures | $44M |
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.
